This section describes efficacy outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the overview.
4.1 A non-randomised comparative study of 267 patients treated by ultra-radical or standard surgery reported no statistically significant difference in overall survival between the 2 groups in patients with optimal cytoreduction (hazard ratio 1.37, 95% confidence interval 0.70 to 2.69, p=0.36). A non-randomised comparative study of 168 patients treated before and 210 patients treated after the introduction of ultra-radical surgery reported 5‑year overall survival rates of 35% and 47% respectively (p=0.03). Median overall survival was 43 months in patients treated before ultra-radical surgery was introduced and 54 months in patients treated after (p=0.03).
4.2 The non-randomised comparative study of 262 patients treated by ultra-radical or standard surgery reported median progression-free survival of 24 months for patients with optimal cytoreduction by ultra-radical surgery, 23 months for patients with optimal cytoreduction by standard surgery and 11 months for patients with suboptimal cytoreduction (p<0.001). The non-randomised comparative study of 378 patients treated either before or after ultra-radical surgery was introduced reported 5‑year progression-free survival rates of 14% and 31% respectively (p=0.01).
4.3 The specialist advisers listed the key efficacy outcomes as disease-free survival, progression-free survival and overall survival.